Edit |   |
---|---|
Antigenic Specificity | CD213α2 (IL-13Rα2), Human |
Clone | REA308 |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG1 |
Format | Vio Bright R720 conjugate |
Size | 100 tests in 200 µL |
Concentration | 1:50 |
Applications | Flow cytometry |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | CD213α2 (IL-13Rα2) Antibody, anti-human, Vio® Bright R720, REAfinity™. Clone REA308 recognizes the human CD213α2 antigen, a single-pass type I membrane protein which is also known as interleukin-13 receptor subunit α-2 (IL-13Rα2). CD213α2 is a high affinity receptor for IL-13 that is used only by IL-13 and is quite distinct from CD213α1 (IL-13Rα1) that IL-13 shares with IL-4. CD213α2 is expressed by fibroblasts, smooth muscle cells, keratinocytes, and activated B cells. It has been thought to be a decoy receptor due to its short cytoplasmic tail and it exists on the cell membrane, intracellularly, and in soluble form. Recent reports revealed that membrane CD213α2 may have some signaling capabilities, and soluble CD213α2 is a critical endogenous modulator for IL-13 responses. Additionally, IL-13 signaling via CD213α2 plays a role in tumor immune surveillance. | Additional information: Clone REA308 displays negligible binding to Fc receptors. |
Immunogen | n/a |
Other Names | IL13RA2, CD213A2, CT19, IL-13R, IL13BP |
Gene, Accession # | Gene ID: 3598 |
Catalog # | 130-130-865 |
Price | $500 |
Order / More Info | CD213α2 (IL-13Rα2), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Andrews, A. L. et al. (2006) IL-13 receptor α2: a regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts. J. Allergy Clin. Immunol. 118 (4): 858-865. | Tabata, Y. et al. (2007) IL-13 receptor isoforms: breaking through the complexity. Curr. Allergy Asthma Rep. 7 (5): 338-345. | Strober, W. et al. (2009) The signaling function of the IL-13Rα2 receptor in the development of gastrointestinal fibrosis and cancer surveillance. Curr. Mol. Med. 9 (6): 740-750. |